Lugano Switzerland (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, announced today that the European Commission has granted the marketing authorisation for their new drug ALOXI®. This announcement comes approximately three months after the CHMP's recommendation to approve ALOXI" for the prevention of acute nausea and vomiting associated with highly ...
Frankfurt, Germany (ots) - AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) announced it has received Colombian Food and Drug Agency approval for Impavido® (miltefosine), to treat the cutaneous form of leishmaniasis, a severe parasitic skin disease estimated to affect millions of people worldwide. This is the first-ever approval of Impavido® for this form of ...
LUGANO, SWITZERLAND, and VIENNA, AUSTRIA (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and CSC, a Pharmaceutical company based in AUSTRIA, announce the signing of an agreement granting CSC the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in Austria and other countries in Central and Eastern Europe. ALOXI® is ...
LUGANO, SWITZERLAND, and Athens, GREECE (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and GALENICA, a Pharmaceutical company based in Greece, announce the signing of an agreement granting GALENICA the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in GREECE. ALOXI® is the second generation of serotonine (5-HT3) ...
DEERFIELD, Ill., and CONCORD, Calif. (ots) - Subsidiaries of Baxter International Inc. (NYSE: BAX) and Cerus Corporation (NASDAQ: CERS) today announced that they have entered into a definitive agreement with BioOne Corporation for commercialization of the INTERCEPT Blood System for platelets in parts of Asia. The ...
Vienna, Austria (ots) - AOP Orphan Pharmaceuticals, manufacturer and product developer of Thromboreductin®, announces that it has achieved its intermediate goal to make Thromboreductin® available in the European Union by means of an ambitious GCP compliant clinical trial programme. Thromboreductin is the first Anagrelide containing medicinal product approved ...
Geneva (ots) - Novo Nordisk Switzerland announced today that Levemir® (insulin detemir), a novel, predictable basal insulin analogue with a unique mechanism of prolonging action (scientifically known as protraction), is available for people with type 1 and type 2 diabetes in Switzerland today. The Swiss launch is just the beginning of an exciting global roll-out of ...
Piscataway, NJ (ots) - Amersham Biosciences, the life sciences business of Amersham (LSE:, NYSE:, OSE: AHM), has enhanced its CodeLink Informatics Solution to help scientists to improve productivity further by streamlining data extraction, acquisition and management processes in their gene expression experiments. The suite of tools includes CodeLink Expression ...
London (ots) - William Ransom & Son plc, the natural healthcare company, announced today a pre-tax profit before amortisation of goodwill of £0.055m in its interim results to 30 September 2003 (pre-tax loss of £0.095m after amortisation of goodwill). The Directors have declared a dividend of 0.50p. In summary: · Turnover declined by 1.6% to £6.731 ...
London, UK (ots) - Antisoma, (LSE: ASM) the biopharmaceutical company specialising in the development of novel anti-cancer drugs, today announces the promotion of Mr Nicholas Adams to Director of Business Development. Nick will lead Antisoma's business development team, for which a key focus remains the acquisition of new products to add to Antisoma's pipeline. He has also been appointed to Antisoma's Executive ...
London (ots) - William Ransom, the natural healthcare company, today confirmed that it is considering the sale of its valuable Hitchin town centre site for residential development. A reorganisation would produce operational savings as pharmaceutical manufacture is transferred to the company's Witham site. Cash ...
London, UK and Princeton, New Jersey USA (ots) - Antisoma plc (LSE: ASM; Nasdaq Europe: ASOM), a United Kingdom-based biopharmaceutical company, and Cytogen Corporation (Nasdaq: CYTO), a United States-based, product-driven, oncology-focused biopharmaceutical company, today announced that Antisoma has acquired certain royalty rights to Antisoma's lead product, R1549 (formerly Pemtumomab), from Cytogen. In connection ...
London, UK (ots) - Antisoma (LSE: ASM- Nasdaq Europe: ASOM), the UK-based biopharmaceutical company, today announces that it has received approval for a voluntary de-listing from the Nasdaq Europe Market. The de-listing of Antisoma shares will be effective from the close of business on Wednesday 10 September ...
Nuremberg, Germany (ots) - With effect from 31 July 2003, the GfK Group will acquire a stake of 51 per cent in pharma market research specialists V2 in Pennsylvania, USA. This acquisition grants GfK access to the most important market for information services relating to pharmaceuticals, biotechnology and medical ...
Madrid (ots) - New data from the VIM study presented today at the annual Congress of the European Society of Ophthalmology (SOE) demonstrate that Visudyne® therapy benefited patients with smaller base line lesions* in minimally classic "wet" AMD, a form of AMD previously considered untreatable.1 Visudyne is the ...
Leverkusen (ots) - The U.S. Food and Drug Administration (FDA) has approved Bayer's antibiotic product Cipro(R) XR (Ciprofloxacin Extended-Release Tablets). This new formulation, given once a day over three days, is designed to treat uncomplicated urinary tract infections (UTIs). Cipro(R) XR will be marketed in a ...
Basel (ots) - Biopharmaceutical company Actelion has become the newest member of Interpharma, the Association of Pharmaceutical Research Companies of Switzerland. Headquartered in Allschwil, canton Baselland, Actelion was accepted as an associate member at Interpharma's most recent general assembly. Associate member status gives Actelion a seat on the expanded Executive Board and on all of the association's task ...
Basel (ots) - * First-quarter Group sales up 13% in local currencies (10% in Swiss francs) * Pharmaceuticals extends double-digit sales growth (+16% in local currencies; +14% in Swiss francs), driven by strong demand for cardiovascular, oncology and ophthalmic products in all regions * Net profits surge ...
Basel, Switzerland (ots) - Biomit Inc., a strategic e-clinical research partner for the biopharmaceutical industry, continues to establish offices throughout Europe as it expands its integrated worldwide representation. Today marks the official opening of its office in Heidelberg, which will coordinate on-line, ...